Found: 8
Select item for more details and to access through your institution.
Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 11, p. 1642, doi. 10.2967/jnumed.122.264299
- By:
- Publication type:
- Article
Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264299
- By:
- Publication type:
- Article
Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264299
- By:
- Publication type:
- Article
Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.122.264299
- By:
- Publication type:
- Article
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy.
- Published in:
- Oncologist, 2019, v. 24, n. 4, p. 563, doi. 10.1634/theoncologist.2018-0084
- By:
- Publication type:
- Article
Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature.
- Published in:
- Vascular Medicine, 2021, v. 26, n. 5, p. 526, doi. 10.1177/1358863X211006470
- By:
- Publication type:
- Article
RE: Is it time to reconsider the role of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma?
- Published in:
- JNCI: Journal of the National Cancer Institute, 2024, v. 116, n. 9, p. 1534, doi. 10.1093/jnci/djae158
- By:
- Publication type:
- Article
Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2024, v. 116, n. 7, p. 1043, doi. 10.1093/jnci/djae066
- By:
- Publication type:
- Article